{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:57:30Z","timestamp":1790035050942,"version":"4.0.1"},"reference-count":30,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"10","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>Denileukin diftitox (DD)-cxdl is a fusion protein comprising diphtheria toxin fragments A and B and human interleukin-2. This phase III, multicenter, open-label, single-arm registrational trial evaluated the efficacy and safety of DD-cxdl in patients with relapsed\/refractory (R\/R) cutaneous T-cell lymphoma (CTCL).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS AND METHODS<\/jats:title>\n            <jats:p>In the main study, which followed a dose-finding lead-in, DD-cxdl was administered intravenously daily (5 days; 9 \u00b5g\/kg\/d once daily) every 21 days for up to eight cycles. Patients in the primary efficacy analysis set (PEAS) were required to have stage IA-IIIB CTCL (mycosis fungoides and\/or S\u00e9zary syndrome) and at least \u2265one previous systemic therapy. The primary efficacy end point was objective response rate (ORR) using the Global Response Score. Secondary end points were duration of response (DOR), time to response (TTR), skin tumor burden, and safety and tolerability.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>The PEAS included 69 patients (median age, 64.0 years). The ORR was 36.2% (95% CI, 25.0 to 48.7), including 8.7% with complete response. The median DOR was 8.9 months (95% CI, 5.0 to not estimable), and the median (Q1-Q3) TTR was 1.4 (0.7-2.1) months. A total of 84.4% of patients showed decreased skin tumor burden, with 48.4% showing a \u226550% decrease. Treatment-emergent adverse events (TEAEs) of special interest, most of which were grade 1 or 2, included infusion reaction (73.9%), hypersensitivity (68.1%), hepatotoxicity (36.2%), and capillary leak syndrome (20.3% [grade \u22653, 5.8%]). Other common TEAEs were nausea (43.5%) and fatigue (31.9%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Efficacy and safety results show that DD-cxdl would potentially fulfill a serious, unmet medical need for patients with R\/R CTCL.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/jco-24-01549","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T20:59:44Z","timestamp":1734641984000},"page":"1198-1209","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma"],"prefix":"10.1200","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct01871727","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7843-3162","authenticated-orcid":true,"given":"Francine M.","family":"Foss","sequence":"first","affiliation":[{"name":"Yale University School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2686-5873","authenticated-orcid":true,"given":"Youn H.","family":"Kim","sequence":"additional","affiliation":[{"name":"Departments of Dermatology &amp; Medicine, Stanford Cancer Center, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0058-2448","authenticated-orcid":true,"given":"H. Miles","family":"Prince","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1339-5710","authenticated-orcid":true,"given":"Oleg E.","family":"Akilov","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center-Presbyterian Shadyside, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Querfeld","sequence":"additional","affiliation":[{"name":"City of Hope Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Seminario-Vidal","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of South Florida, Tampa, FL"},{"name":"Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Fisher","sequence":"additional","affiliation":[{"name":"Dana-Faber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7523-2397","authenticated-orcid":true,"given":"Timothy M.","family":"Kuzel","sequence":"additional","affiliation":[{"name":"Rush University Medical Center, Chicago, IL"},{"name":"Department of Medicine, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6657-2034","authenticated-orcid":true,"given":"Costas K.","family":"Yannakou","sequence":"additional","affiliation":[{"name":"Epworth HealthCare, Melbourne, Australia"},{"name":"Department of Clinical Pathology, University of Melbourne, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa J.","family":"Geskin","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Feldman","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center at Hackensack Meridian Health, Hackensack, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubomir","family":"Sokol","sequence":"additional","affiliation":[{"name":"H. Lee Moffit Cancer Center and Research Institute, Inc., Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3959-3662","authenticated-orcid":true,"given":"Pamela Blair","family":"Allen","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam Hoang","family":"Dang","sequence":"additional","affiliation":[{"name":"University of Florida Health Shands Hospital, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9234-7893","authenticated-orcid":true,"given":"Fernando","family":"Cabanillas","sequence":"additional","affiliation":[{"name":"Hospital Espa\u00f1ol Auxilio Mutuo\/Auxilio Mutuo Cancer Center, San Juan, PR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry K.","family":"Wong","sequence":"additional","affiliation":[{"name":"University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chean Eng","family":"Ooi","sequence":"additional","affiliation":[{"name":"Eisai Inc., Nutley, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyuan","family":"Xing","sequence":"additional","affiliation":[{"name":"Citius Pharmaceuticals, Cranford, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Sauter","sequence":"additional","affiliation":[{"name":"Eisai Inc., Nutley, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeti","family":"Singh","sequence":"additional","affiliation":[{"name":"Citius Pharmaceuticals, Cranford, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron","family":"Czuczman","sequence":"additional","affiliation":[{"name":"Citius Pharmaceuticals, Cranford, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The University of Texas\u2014MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_9_2_2","first-page":"10","article-title":"Cutaneous lymphomas\u2014Fast facts about an orphan disease\u2014A short review","volume":"16","author":"Porkert S","year":"2023","unstructured":"Porkert S, Valencak J: Cutaneous lymphomas\u2014Fast facts about an orphan disease\u2014A short review. memo\u2014Mag Eur Med Oncol 16:10-16, 2023","journal-title":"memo\u2014Mag Eur Med Oncol"},{"key":"e_1_3_9_3_2","first-page":"5","article-title":"Epidemiology of non-Hodgkin's lymphoma","volume":"9","author":"Thandra KC","year":"2021","unstructured":"Thandra KC, Barsouk A, Saginala K, et al: Epidemiology of non-Hodgkin's lymphoma. Med Sci (Basel) 9:5, 2021","journal-title":"Med Sci (Basel)"},{"key":"e_1_3_9_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102921"},{"key":"e_1_3_9_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.3236"},{"key":"e_1_3_9_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2850"},{"key":"e_1_3_9_7_2","unstructured":"National Comprehensive Cancer Network (NCCN): NCCN Clinical Practice Guidelines in Oncology. Primary cutaneous lymphomas. Version 1.2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/primary_cutaneous.pdf"},{"key":"e_1_3_9_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-055749"},{"key":"e_1_3_9_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.07.712"},{"key":"e_1_3_9_10_2","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.21922.1"},{"key":"e_1_3_9_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26299"},{"key":"e_1_3_9_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2003.05698.x"},{"key":"e_1_3_9_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17117"},{"key":"e_1_3_9_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy133"},{"key":"e_1_3_9_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010145"},{"key":"e_1_3_9_16_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.5.1.33"},{"key":"e_1_3_9_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.376"},{"key":"e_1_3_9_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)50310-6"},{"key":"e_1_3_9_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-532531"},{"key":"e_1_3_9_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-6-12"},{"key":"e_1_3_9_21_2","unstructured":"ONTAK (denileukin diftitox) [prescribing information]. Ridgefield Park NJ Eisai Medical Research Inc 2020"},{"key":"e_1_3_9_22_2","unstructured":"U.S. Food and Drug Administration: Denileukin diftitox\u2014Product approval information\u2014Licensing action. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/1999\/denser020599L.htm"},{"key":"e_1_3_9_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13513"},{"key":"e_1_3_9_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14906"},{"key":"e_1_3_9_25_2","unstructured":"Eisai launches Remitoro for PTCL and CTCL in Japan. The Pharma Letter. https:\/\/www.thepharmaletter.com\/article\/eisai-launches-remitoro-for-ptcl-and-ctcl-in-japan"},{"key":"e_1_3_9_26_2","unstructured":"LYMPHIR\u2122 (denileukin diftitox-cxdl) [prescribing information]. Cranford NJ Citius Pharmaceuticals Inc 2024"},{"key":"e_1_3_9_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2386"},{"key":"e_1_3_9_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-018-0638-z"},{"key":"e_1_3_9_29_2","unstructured":"Citius Pharmaceuticals Inc: Biologics license application for E7777. Submitted to the U.S. FDA October 2022. Data on file"},{"key":"e_1_3_9_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.0630"},{"key":"e_1_3_9_31_2","unstructured":"U.S. Department of Health and Human Services: Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-24-01549","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T22:09:19Z","timestamp":1743199759000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-24-01549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1200\/JCO-24-01549"],"URL":"https:\/\/doi.org\/10.1200\/jco-24-01549","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2024-07-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}